NasdaqGM - Nasdaq Real Time Price USD
KalVista Pharmaceuticals, Inc. (KALV)
As of 10:32 AM EST. Market Open.
Breakdown
TTM
4/30/2024
4/30/2023
4/30/2022
4/30/2021
Operating Expense
147,115.00
131,993.00
95,086.00
81,310.00
57,923.00
Operating Income
-147,115.00
-131,993.00
-95,086.00
-81,310.00
-57,923.00
Net Non Operating Interest Income Expense
4,665.00
3,896.00
2,232.00
1,090.00
903.00
Other Income Expense
680.00
1,453.00
-53.00
-2,119.00
10,776.00
Pretax Income
-141,770.00
-126,644.00
-92,907.00
-82,339.00
-46,244.00
Net Income Common Stockholders
-141,770.00
-126,644.00
-92,907.00
-82,339.00
-46,244.00
Diluted NI Available to Com Stockholders
-141,770.00
-126,644.00
-92,907.00
-82,339.00
-46,244.00
Basic EPS
-3.57
-3.44
-3.33
-3.36
-2.42
Diluted EPS
-3.57
-3.44
-3.33
-3.36
-2.42
Basic Average Shares
39,741.26
36,786.58
27,890.85
24,473.09
19,094.44
Diluted Average Shares
39,741.26
36,786.58
27,890.85
24,473.09
19,094.44
Total Operating Income as Reported
-155,567.00
-140,445.00
-110,871.00
-96,613.00
-57,923.00
Total Expenses
147,115.00
131,993.00
95,086.00
81,310.00
57,923.00
Net Income from Continuing & Discontinued Operation
-141,770.00
-126,644.00
-92,907.00
-82,339.00
-46,244.00
Normalized Income
-143,291.00
-128,107.00
-92,858.00
-80,221.00
-47,091.00
Interest Income
4,665.00
3,896.00
2,232.00
1,090.00
903.00
Net Interest Income
4,665.00
3,896.00
2,232.00
1,090.00
903.00
EBIT
-147,115.00
-131,993.00
-95,086.00
-81,310.00
-57,923.00
EBITDA
-146,268.00
-131,177.00
-94,368.00
-80,746.00
-57,386.00
Reconciled Depreciation
847.00
816.00
718.00
564.00
537.00
Net Income from Continuing Operation Net Minority Interest
-141,770.00
-126,644.00
-92,907.00
-82,339.00
-46,244.00
Total Unusual Items Excluding Goodwill
1,521.00
1,463.00
-49.00
-2,118.00
847.00
Total Unusual Items
1,521.00
1,463.00
-49.00
-2,118.00
847.00
Normalized EBITDA
-147,789.00
-132,640.00
-94,319.00
-78,628.00
-58,233.00
4/30/2021 - 4/9/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PHVS Pharvaris N.V.
22.80
+2.15%
ASND Ascendis Pharma A/S
127.10
+0.43%
IRON Disc Medicine, Inc.
65.50
+3.43%
MRUS Merus N.V.
54.11
-0.72%
KROS Keros Therapeutics, Inc.
66.43
-1.10%
SNDX Syndax Pharmaceuticals, Inc.
21.86
+1.58%
ANAB AnaptysBio, Inc.
21.56
+0.33%
KURA Kura Oncology, Inc.
17.49
-1.58%
PTGX Protagonist Therapeutics, Inc.
45.68
-4.05%
ATXS Astria Therapeutics, Inc.
11.57
-1.69%